Our top pick for
Bio-Techne Corporation is a biotechnology business based in the US. Bio-Techne Corporation shares (TECH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio-Techne Corporation employs 2,300 staff and has a trailing 12-month revenue of around USD$738.7 million.
|52-week range||USD$155.17 - USD$286.68|
|50-day moving average||USD$251.928|
|200-day moving average||USD$251.9229|
|Wall St. target price||USD$299.33|
|Dividend yield||USD$1.28 (0.48%)|
|Earnings per share (TTM)||USD$5.82|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Bio-Techne Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Techne Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bio-Techne Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 46x. In other words, Bio-Techne Corporation shares trade at around 46x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Bio-Techne Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.511. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Techne Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bio-Techne Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$199 million.
The EBITDA is a measure of a Bio-Techne Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$738.7 million|
|Operating margin TTM||20.41%|
|Gross profit TTM||USD$483.2 million|
|Return on assets TTM||4.82%|
|Return on equity TTM||18.01%|
|Market capitalisation||USD$10.3 billion|
TTM: trailing 12 months
There are currently 585,113 Bio-Techne Corporation shares held short by investors – that's known as Bio-Techne Corporation's "short interest". This figure is 2.7% up from 569,507 last month.
There are a few different ways that this level of interest in shorting Bio-Techne Corporation shares can be evaluated.
Bio-Techne Corporation's "short interest ratio" (SIR) is the quantity of Bio-Techne Corporation shares currently shorted divided by the average quantity of Bio-Techne Corporation shares traded daily (recently around 187536.21794872). Bio-Techne Corporation's SIR currently stands at 3.12. In other words for every 100,000 Bio-Techne Corporation shares traded daily on the market, roughly 3120 shares are currently held short.
However Bio-Techne Corporation's short interest can also be evaluated against the total number of Bio-Techne Corporation shares, or, against the total number of tradable Bio-Techne Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bio-Techne Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Bio-Techne Corporation shares in existence, roughly 20 shares are currently held short) or 0.017% of the tradable shares (for every 100,000 tradable Bio-Techne Corporation shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bio-Techne Corporation.
Find out more about how you can short Bio-Techne Corporation stock.
Dividend payout ratio: 28.26% of net profits
Recently Bio-Techne Corporation has paid out, on average, around 28.26% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.48% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bio-Techne Corporation shareholders could enjoy a 0.48% return on their shares, in the form of dividend payments. In Bio-Techne Corporation's case, that would currently equate to about $1.28 per share.
While Bio-Techne Corporation's payout ratio might seem fairly standard, it's worth remembering that Bio-Techne Corporation may be investing much of the rest of its net profits in future growth.
Bio-Techne Corporation's most recent dividend payout was on 28 August 2020. The latest dividend was paid out to all shareholders who bought their shares by 17 August 2020 (the "ex-dividend date").
Bio-Techne Corporation's shares were split on a 2:1 basis on 4 December 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bio-Techne Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Bio-Techne Corporation shares which in turn could have impacted Bio-Techne Corporation's share price.
Over the last 12 months, Bio-Techne Corporation's shares have ranged in value from as little as $155.17 up to $286.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Techne Corporation's is 0.9763. This would suggest that Bio-Techne Corporation's shares are less volatile than average (for this exchange).
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Steps to owning and managing DRIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing CYBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHCI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CKX, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTHR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CNBKA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CATM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRME, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.